Are molecular target therapies limited by cardiotoxicity — causes and symptoms of cardiovascular damage

Streszczenie

Since the introduction of new drugs, (commonly referred to as ‘Molecular Target Therapies’), into oncological clinical practice both the number of objective indicators/endpoints of achieved treatment response and cancer survival duration have increased. Nevertheless, the risk of cardiovascular complications has also risen. Optimistic reports on the relatively low cardiotoxicity of these drugs have been verified through experience. Routine clinical practice has witnessed growing numbers of new drug groups that have different molecular target points and also a varied cardiotoxicity.

This paper presents the most important cardiovascular complications associated with the use of molecularly targeted drugs and includes their mechanisms of development.